4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Ahmad R. Safa, Mohammad Reza Saadatzadeh, Aaron A. Cohen-Gadol, Karen E. Pollok, Khadijeh Bijangi-Vishehsaraei. Emerging targets for glioblastoma stem cell therapy[J]. The Journal of Biomedical Research, 2016, 30(1): 19-31. DOI: 10.7555/JBR.30.20150100
Citation: Ahmad R. Safa, Mohammad Reza Saadatzadeh, Aaron A. Cohen-Gadol, Karen E. Pollok, Khadijeh Bijangi-Vishehsaraei. Emerging targets for glioblastoma stem cell therapy[J]. The Journal of Biomedical Research, 2016, 30(1): 19-31. DOI: 10.7555/JBR.30.20150100

Emerging targets for glioblastoma stem cell therapy

Funds: 

the National Cancer Institute of the National Institutes of Health under award number RO1CA138798 (KP), the Riley Children's Foundation, the Jeff Gordon Children's Foundation (KP), and the support of the IUPUI Signature Center Initiative for the Cure of Glioblastoma

More Information
  • Received Date: July 13, 2015
  • Revised Date: July 26, 2015
  • Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, is a lethal and therapy-resistant brain cancer comprised of several tumor cell subpopulations, including GBM stem cells (GSCs) which are believed to contribute to tumor recurrence following initial response to therapies. Emerging evidence demonstrates that GBM tumors are initiated from GSCs. The development and use of novel therapies including small molecule inhibitors of specific proteins in signaling pathways that regulate stemness, proliferation and migration of GSCs, immunotherapy, and non-coding microRNAs may provide better means of treating GBM. Identification and characterization of GSC-specific signaling pathways would be necessary to identify specific therapeutic targets which may lead to the development of more efficient therapies selectively targeting GSCs. Several signaling pathways including mTOR, AKT, maternal embryonic leucine zipper kinase (MELK), NOTCH1 and Wnt/b-catenin as well as expression of cancer stem cell markers CD133, CD44, Oct4, Sox2, Nanog, and ALDH1A1 maintain GSC properties. Moreover, the data published in the Cancer Genome Atlas (TCGA) specifically demonstrated the activated PI3K/AKT/mTOR pathway in GBM tumorigenesis. Studying such pathways may help to understand GSC biology and lead to the development of potential therapeutic interventions to render them more sensitive to chemotherapy and radiation therapy. Furthemore, recent demonstration of dedifferentiation of GBM cell lines into CSC-like cells prove that any successful therapeutic agent or combination of drugs for GBM therapy must eliminate not only GSCs, but the differentiated GBM cells and the entire bulk of tumor cells.
  • Related Articles

    [1]Izzatullo Ziyoyiddin o`g`li Abdullaev, Ulugbek Gapparjanovich Gayibov, Sirojiddin Zoirovich Omonturdiev, Sobirova Fotima Azamjonovna, Sabina Narimanovna Gayibova, Takhir Fatikhovich Aripov. Molecular pathways in cardiovascular disease under hypoxia: Mechanisms, biomarkers, and therapeutic targets[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240387
    [2]Chen Li, Kerui Wang, Xingfeng Mao, Xiuxiu Liu, Yingmei Lu. Upregulated inwardly rectifying K+ current-mediated hypoactivity of parvalbumin interneuron underlies autism-like deficits in Bod1-deficient mice[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240394
    [3]Kim Byung Cheol, Song Jae-In, So Kyoung-Ha, Hyun Sang-Hwan. Effects of lysophosphatidic acid on human periodontal ligament stem cells from teeth extracted from dental patients[J]. The Journal of Biomedical Research, 2019, 33(2): 122-130. DOI: 10.7555/JBR.32.20170123
    [4]Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
    [5]Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
    [6]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [7]Christopher J. Danford, Zemin Yao, Z. Gordon Jiang. Non-alcoholic fatty liver disease: a narrative review of genetics[J]. The Journal of Biomedical Research, 2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045
    [8]Tian Tian, Yajie Zhang, Shouyu Wang, Jianwei Zhou, Shan Xua. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer[J]. The Journal of Biomedical Research, 2012, 26(5): 336-345. DOI: 10.7555/JBR.26.20120045
    [9]Xiaoyan Wang, Guozhu Wang, Yi Zhao, Xiaoan Liu, Qiang Ding, Jingping Shi, Yin Ding, Shui Wang. STAT3 mediates resistance of CD44+CD24-/low breast cancer stem cells to tamoxifen in vitro[J]. The Journal of Biomedical Research, 2012, 26(5): 325-335. DOI: 10.7555/JBR.26.20110050
    [10]Bo Cui, Stewart P. Johnson, Nancy Bullock, Francis Ali-Osman, Darell D. Bigner, Henry S. Friedman. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells[J]. The Journal of Biomedical Research, 2010, 24(6): 424-435. DOI: 10.1016/S1674-8301(10)60057-7
  • Cited by

    Periodical cited type(27)

    1. Boda VK, Yasmen N, Jiang J, et al. Pathophysiological significance and modulation of the transient receptor potential canonical 3 ion channel. Med Res Rev, 2024, 44(6): 2510-2544. DOI:10.1002/med.22048
    2. Agrawal K, Asthana S, Kumar D. Role of Oxidative Stress in Metabolic Reprogramming of Brain Cancer. Cancers (Basel), 2023, 15(20): 4920. DOI:10.3390/cancers15204920
    3. Zhou Y, Pereira G, Tang Y, et al. 3D Porous Scaffold-Based High-Throughput Platform for Cancer Drug Screening. Pharmaceutics, 2023, 15(6): 1691. DOI:10.3390/pharmaceutics15061691
    4. Safa AR. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces. Cancer Drug Resist, 2022, 5(4): 850-872. DOI:10.20517/cdr.2022.20
    5. Gal O, Betzer O, Rousso-Noori L, et al. Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy. J Nanotheranostics, 2022, 3(4): 177-188. DOI:10.3390/jnt3040012
    6. Scioli MG, Terriaca S, Fiorelli E, et al. Extracellular Vesicles and Cancer Stem Cells in Tumor Progression: New Therapeutic Perspectives. Int J Mol Sci, 2021, 22(19): 10572. DOI:10.3390/ijms221910572
    7. Keyvani-Ghamsari S, Khorsandi K, Rasul A, et al. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenetics, 2021, 13(1): 120. DOI:10.1186/s13148-021-01107-4
    8. Safa AR. Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci, 2020, 6(3): 341. DOI:10.15761/jts.1000341
    9. Chandimali N, Koh H, Kim J, et al. BRM270 targets cancer stem cells and augments chemo-sensitivity in cancer. Oncol Lett, 2020, 20(4): 103. DOI:10.3892/ol.2020.11964
    10. Mukherjee S. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples. Sci Rep, 2020, 10(1): 10937. DOI:10.1038/s41598-020-67753-5
    11. Zhou JJ, Xiao Y, Li H, et al. Overexpression of Malic Enzyme 2 Indicates Pathological and Clinical Significance in Oral Squamous Cell Carcinoma. Int J Med Sci, 2020, 17(6): 799-806. DOI:10.7150/ijms.43832
    12. Sun Z, Wang L, Zhou Y, et al. Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein. Cell Mol Neurobiol, 2020, 40(5): 767-784. DOI:10.1007/s10571-019-00771-8
    13. Zhang Q, Xu B, Chen J, et al. Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival. J Clin Lab Anal, 2020, 34(3): e23082. DOI:10.1002/jcla.23082
    14. Megías J, Martínez A, San-Miguel T, et al. Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide. Invest New Drugs, 2020, 38(2): 299-310. DOI:10.1007/s10637-019-00788-2
    15. Li Z, Chen Y, An T, et al. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway. J Exp Clin Cancer Res, 2019, 38(1): 139. DOI:10.1186/s13046-019-1134-y
    16. Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med, 2018, 7(1): 33. DOI:10.1186/s40169-018-0211-8
    17. Grande S, Palma A, Ricci-Vitiani L, et al. Metabolic Heterogeneity Evidenced by MRS among Patient-Derived Glioblastoma Multiforme Stem-Like Cells Accounts for Cell Clustering and Different Responses to Drugs. Stem Cells Int, 2018, 2018: 3292704. DOI:10.1155/2018/3292704
    18. Zuccarini M, Giuliani P, Ziberi S, et al. The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor. Genes (Basel), 2018, 9(2): 105. DOI:10.3390/genes9020105
    19. Bhere D, Tamura K, Wakimoto H, et al. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncol, 2018, 20(2): 215-224. DOI:10.1093/neuonc/nox138
    20. Lee S, Kwon MC, Jang JP, et al. The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells. Int J Oncol, 2017, 51(2): 414-424. DOI:10.3892/ijo.2017.4054
    21. Jovčevska I, Zupanec N, Urlep Ž, et al. Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget, 2017, 8(27): 44141-44158. DOI:10.18632/oncotarget.17390
    22. Hiramatsu H, Kobayashi K, Kobayashi K, et al. The role of the SWI/SNF chromatin remodeling complex in maintaining the stemness of glioma initiating cells. Sci Rep, 2017, 7(1): 889. DOI:10.1038/s41598-017-00982-3
    23. Zheng X, Pang B, Gu G, et al. Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis. Int J Biol Sci, 2017, 13(2): 245-253. DOI:10.7150/ijbs.16818
    24. Bijangi-Vishehsaraei K, Reza Saadatzadeh M, Wang H, et al. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. J Neurosurg, 2017, 127(6): 1219-1230. DOI:10.3171/2016.8.JNS161197
    25. Majewska E, Szeliga M. AKT/GSK3β Signaling in Glioblastoma. Neurochem Res, 2017, 42(3): 918-924. DOI:10.1007/s11064-016-2044-4
    26. Kanabur P, Guo S, Simonds GR, et al. Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget, 2016, 7(52): 86406-86419. DOI:10.18632/oncotarget.13415
    27. Wang K, Kievit FM, Erickson AE, et al. Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells. Adv Healthc Mater, 2016, 5(24): 3173-3181. DOI:10.1002/adhm.201600684

    Other cited types(0)

Catalog

    Article Metrics

    Article views (4644) PDF downloads (727) Cited by(27)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return